TransTech Pharma Inc. reacquired all rights to a glucokinase activator program that it had partnered with Novo Nordisk A/S more than five years ago, increasing an already healthy pipeline in the area of diabetes. (BioWorld Today)
TransTech Pharma Inc. reacquired all rights to a glucokinase activator program that it had partnered with Novo Nordisk A/S more than five years ago, increasing an already healthy pipeline in the area of diabetes. (BioWorld Today)
Halozyme Therapeutics Inc. significantly expanded its relationships with Baxter Healthcare Corp., continuing momentum at the company that gained full steam two months ago. (BioWorld Today)
Halozyme Therapeutics Inc. significantly expanded its relationships with Baxter Healthcare Corp., continuing momentum at the company that gained full steam two months ago. (BioWorld Today)
Omeros Corp. set out to raise $20 million in its Series E financing round, but ended up bringing in more than $63 million by the time it was all over. (BioWorld Today)
